IL2 and Increased total eosinophil count: The trial reported no treatment-related mortality and a similar frequency of grades 3 and 4 events in both study arms.13 Patients in the HDC/IL-2 arm experienced transient flush, mild hypotension, transient headache, eosinophilia (albeit devoid of related morbidity), transient low-grade fever, and transient injection site reactions to IL-2.